UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 23, 2014
|
Sanomedics International Holdings, Inc.
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
000-54167
|
27-3320809
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
444 Brickell Avenue, Suite 415, Miami, Florida
|
33131
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code (305)433-7814
|
not applicable
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
As previously reported on Form 8-K on August 27, 2013, Sanomedics International Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement with Asher Enterprises, Inc. (“Asher”) for the sale of a convertible promissory note (the “Note”) in the principal amount of $73,500 which was executed and funded on August 30, 2013. On January 22, 2014, the Company paid $97,740 to Asher in order to satisfy the Note. The amount of the payoff includes accrued interest and default amount. The Note was due on May 29, 2014, bears interest at 8% per annum until paid or to maturity. The Note is now paid in full and the Company has no further obligation with respect to the Note.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Sanomedics International Holdings, Inc. | |||
|
Date: January 23, 2014
|
By:
|
/s/ David C. Langle | |
| David C. Langle, Chief Financial Officer | |||
3